Relative contribution of incretins to the glucose lowering effect of DP IV inhibitors in type 2 diabetes mellitus (T2DM)

被引：0
作者：
Hinke, Simon A.
Pederson, Raymond A.
McIntosh, Christopher H. S.
机构：
[1] Vrije Univ Brussel, Diabet Res Ctr, Dept Metab & Endocrinol, B-1090 Brussels, Belgium
[2] Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada
来源：
DIPEPTIDYL AMINOPEPTIDASES: BASIC SCIENCE AND CLINICAL APPLICATIONS | 2006年 / 575卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：119 / 133
页数：15
相关论文
共 96 条
[1]   Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice [J].
Ahrén, B ;
Holst, JJ ;
Mårtensson, H ;
Balkan, B .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 404 (1-2) :239-245
[2]   Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice [J].
Ahrén, B ;
Hughes, TE .
ENDOCRINOLOGY, 2005, 146 (04) :2055-2059
[3]   Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [J].
Ahrén, B ;
Landin-Olsson, M ;
Jansson, PA ;
Svensson, M ;
Holmes, D ;
Schweizer, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2078-2084
[4]   Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes [J].
Ahrén, B ;
Gomis, R ;
Standl, E ;
Mills, D ;
Schweizer, A .
DIABETES CARE, 2004, 27 (12) :2874-2880
[5]   Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice [J].
Baggio, L ;
Kieffer, TJ ;
Drucker, DJ .
ENDOCRINOLOGY, 2000, 141 (10) :3703-3709
[6]   The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport [J].
Cheeseman, CI ;
Tsang, R .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1996, 271 (03) :G477-G482
[7]   NEW DEVELOPMENTS IN THE INCRETIN CONCEPT [J].
CREUTZFELDT, W ;
EBERT, R .
DIABETOLOGIA, 1985, 28 (08) :565-573
[8]   Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide [J].
Deacon, CF ;
Nauck, MA ;
Meier, J ;
Hücking, K ;
Holst, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3575-3581
[9]   Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs [J].
Deacon, CF ;
Wamberg, S ;
Bie, P ;
Hughes, TE ;
Holst, JJ .
JOURNAL OF ENDOCRINOLOGY, 2002, 172 (02) :355-362
[10]   Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig [J].
Deacon, CF ;
Hughes, TE ;
Holst, JJ .
DIABETES, 1998, 47 (05) :764-769
12345678910